West Pharmaceutical Services, Inc. logo
WSTWest Pharmaceutical Services, Inc.

The forward PE ratio is 41.06 as of Thursday, July 9, 2026.

Forward PE Ratio (41.06) = Close Price ($357.66) / Consensus Forward EPS ($8.61)

WST Forward PE Ratio Metrics

FORWARD PE RATIO

41.06

WST Competitors' Forward PE Ratio

WST

West Pharmaceutical Services, Inc.

Current

Market Cap

$25.27B

Forward PE Ratio

41.06

WAT

Waters Corporation

vs WST

Market Cap

$24.58B

Forward PE Ratio

25.34

MTD

Mettler-Toledo International Inc.

vs WST

Market Cap

$26.03B

Forward PE Ratio

26.75

INCY

Incyte Corporation

vs WST

Market Cap

$23.68B

Forward PE Ratio

15.33

BNTX

BioNTech SE

vs WST

Market Cap

$23.51B

Forward PE Ratio

N/A

UTHR

United Therapeutics Corporation

vs WST

Market Cap

$23.45B

Forward PE Ratio

19.75

DGX

Quest Diagnostics Incorporated

vs WST

Market Cap

$23.03B

Forward PE Ratio

19.37

LH

Labcorp Holdings Inc.

vs WST

Market Cap

$22.77B

Forward PE Ratio

15.42

DXCM

DexCom, Inc.

vs WST

Market Cap

$28.18B

Forward PE Ratio

28.55

BIIB

Biogen Inc.

vs WST

Market Cap

$29.37B

Forward PE Ratio

13.80

Trailing vs Forward

Trailing P/E

47.2

reported TTM EPS

Forward P/E

41.1

consensus next-FY EPS

The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $8.61 implies +15.0% EPS growth vs the reported trailing $7.49.

Forward P/E by Fiscal Year

View All Analyst Estimates

At today's $357.66 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.

Fiscal year endConsensus EPSEstimate rangeAnalystsImplied P/E
2026-12-31$8.61$8.51 – $8.66941.5x
2027-12-31$9.59$9.33 – $9.85937.3x
2028-12-31$10.87$10.30 – $11.76332.9x

Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.

Forward PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Forward PE Ratio FAQ

What is the forward PE ratio for West Pharmaceutical Services, Inc. (WST)?
The forward PE ratio for WST stock is 41.06.

About West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.

Exton, PA
10,600 employees
Healthcare / Medical - Instruments & Supplies
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Eric Green